Highlighting “Trickle Down” Progress in Developing Rare Lymphoma Treatment
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
71 Beyond the Surface: Suspicious Nipple Lesions
Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC
Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.
Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC
Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.
FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC
Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.
Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer
Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.
Concurrent Chemoradiation May Improve LS-SCLC Prognosis
Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.
Cemsidomide Combo May Produce Responses in Multiple Myeloma
Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.
Perseverance Underscores Success in Rare Lymphoma Research
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes
FDA Gives Fast Track Designation to ISB 2001 in Relapsed/Refractory Myeloma
Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.
Ileal Free Flap Urethroplasty May Remedy Devastated Bladder Outlet
A new type of robotic posterior surgery has been shown to be a treatment option for patients with devastated bladder outlets.
T-DXd Plus THP Bolsters Pathologic Responses in Early-Stage Breast Cancer
Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.
FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease
Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related post-transplant lymphoproliferative disease.
Atezolizumab/Trastuzumab Plus Chemotherapy Shows Efficacy in Gastric Cancer
Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.
Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma
Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?
Leveraging Beta and Alpha Emitters in Metastatic CRPC Management
Beta emitters such as lutetium Lu 177 rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Neurovascular Sparing during Radiation Reduces Incidence of ED in Prostate Cancer
The 1.5T Elekta Unity MR-Linac demonstrated lower rates of erectile dysfunction with neurovascular sparing vs without in patients with intermediate-risk prostate cancer.
FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera
The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.
HITOCH After Surgery Appears Safe, May Improve Survival in Mesothelioma
A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.
TAR-200 Might Be “Best in Class” for BCG-Unresponsive High-Risk NMIBC
Results from cohort 4 of the phase 2 SunRISe-1 trial showed TAR-200 elicited a 6- and 9-month DFS rate of 85.3% and 81.1%, respectively, in BCG-unresponsive NMIBC.
Data Show Racial/Ethnic Disparities in Pediatric Brain Cancer Survival
Clinical trial access alone appears to be insufficient in overcoming the worse survival outcomes observed in Black and Hispanic pediatric populations.
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center
FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept in NMIBC
The FDA refuses to file the sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with papillary disease without carcinoma in situ.
Workplace Burnout Among Oncologists Has Risen: What Can Be Done?
Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.
JNJ-1900 Demonstrates Safety, Feasibility in Advanced Pancreatic Cancer
Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.
Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia
Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.
75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial
!["Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ffc2a0cb8c6d287fa539f7d61aad18a8752d347dc-1200x882.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option,\" according to the study authors.")
